Le Lézard
Classified in: Health, Business, Covid-19 virus
Subjects: LGB, FVT, DEI

Meridian of Michigan Sponsors Motor City Pride and Provides Community Health Services


Wayne Health Mobile Unit will provide COVID-19 vaccines and tests during festival

DETROIT, June 9, 2022 /PRNewswire/ -- Meridian of Michigan, a leading provider of government-sponsored health plans in the state, is a proud sponsor of the 50th annual Motor City Pride Festival and Parade, Michigan's largest Pride celebration, and will provide all attendees the opportunity to get their COVID-19 vaccine and other health screenings, regardless of membership status.

"Meridian takes pride in providing quality healthcare and support to all of our community members," said Sean Kendall, Meridian of Michigan President and CEO. "We are committed to helping create a more equitable, diverse, and inclusive community where we can support our LGBTQ+ community members by doing our part to keep attendees safe and healthy during the celebration."

While COVID-19 cases in Michigan have sharply declined, it is still important to remain ever-vigilant, especially as warm weather draws family, friends, and neighbors together. During the festival, Meridian will partner with Wayne Health Mobile Unit to provide COVID vaccines and tests during the festival, as well as blood pressure screenings and other free health services to members of the community.

The Motor City Pride festival runs June 11-12 and will conclude Sunday with a parade starting at noon. In addition to celebration's events, Meridian will continue to partner with mobile health clinics and other community partners to educate members and the public and to take the vaccine into communities across the state via various events.

About Meridian
Meridian of Michigan provides government-sponsored managed care services to families, children, seniors, and individuals with complex medical needs primarily through Medicaid (MeridianHealth), Medicare Advantage (Wellcare), Medicare-Medicaid Plans (MeridianComplete), and the Health Insurance Marketplace (Ambetter from Meridian). Meridian is a wholly owned subsidiary of Centene Corporation, a leading healthcare enterprise committed to helping people live healthier lives. For more information about Meridian, visit mimeridian.com.

 

SOURCE Meridian of Michigan


These press releases may also interest you

at 04:45
ERS Genomics and IRBM Sign CRISPR/Cas9 License Agreement
ERS Genomics Limited (?ERS'), the CRISPR licensing Company, and IRBM, a leader in the field of drug discovery, today announced a non-exclusive CRISPR/Cas9 license agreement. The agreement grants IRBM access to ERS' CRISPR/Cas9 patent portfolio....

at 03:15
Cresilon Announces International Distribution Agreement for VETIGEL with Covetrus
Cresilon Inc. ("Cresilon"), a Brooklyn-based biotechnology company focused on haemostatic medical device technologies, today announced it has entered into a distribution agreement for its revolutionary haemostatic gel, VETIGEL®, to be sold directly...

at 02:30
New Research by Tea Advisory Panel Reveals That Three Quarters Of Brits Never Drink Tea Before A Workout Despite It Counting Towards Fluid Intake Recommendations
Ahead of International Tea Day - 21st May 2024  - and with summer inspiring more of us to get off the sofa to be active, a 2024 real-world research study1 reviewed by the tea science experts at the Tea Advisory Panel ? www.teaadvisorypanel.com -...

at 02:30
TREEFROG PRESENTS DATA FROM THEIR PARKINSON'S DISEASE CELL THERAPY PROGRAM AT THE 29TH WORLD CONGRESS ON PARKINSON'S DISEASE AND RELATED DISORDERS (IAPRD) IN LISBON
TreeFrog Therapeutics will participate for the first time at the IAPRD, to present data from their Parkinson's disease cell therapy program, which has demonstrated excellent results with full motor recovery at 16 weeks in preclinical studies.[1]...

at 02:20
Vicore Announces Positive Final Results from the Phase 2a AIR Trial Demonstrating Buloxibutid Improves Lung Function Over 36 Weeks in Patients with Idiopathic Pulmonary Fibrosis
Vicore Pharma Holding (STO:VICO)Buloxibutid improved lung function-measured by FVC-by over 200 mL from baseline at 36 weeks of treatment.The therapy was safe and well tolerated with no treatment-related serious adverse events.Biomarker analysis...

at 02:07
GC Biopharma/Novel Pharma's Sanfilippo Syndrome Treatment Obtains FDA IND Approval
GC Biopharma (006280. KS) and Novel Pharma announced that its jointly developed MPS IIIA 'GC1130A' treatment has received FDA IND approval....

More news about Health...


News published on and distributed by: